vs

Side-by-side financial comparison of Arbutus Biopharma Corp (ABUS) and PROVIDENT FINANCIAL HOLDINGS INC (PROV). Click either name above to swap in a different company.

Arbutus Biopharma Corp is the larger business by last-quarter revenue ($10.7M vs $9.8M, roughly 1.1× PROVIDENT FINANCIAL HOLDINGS INC). Arbutus Biopharma Corp runs the higher net margin — 23.5% vs 14.6%, a 8.9% gap on every dollar of revenue. On growth, Arbutus Biopharma Corp posted the faster year-over-year revenue change (522.2% vs 2.5%). Over the past eight quarters, PROVIDENT FINANCIAL HOLDINGS INC's revenue compounded faster (2.3% CAGR vs -13.2%).

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.

Provident Financial Holdings Inc is a bank holding company operating through its subsidiary Provident Savings Bank. It offers retail and commercial banking services including deposit products, mortgage loans, consumer lending and small business financing for local communities across California.

ABUS vs PROV — Head-to-Head

Bigger by revenue
ABUS
ABUS
1.1× larger
ABUS
$10.7M
$9.8M
PROV
Growing faster (revenue YoY)
ABUS
ABUS
+519.7% gap
ABUS
522.2%
2.5%
PROV
Higher net margin
ABUS
ABUS
8.9% more per $
ABUS
23.5%
14.6%
PROV
Faster 2-yr revenue CAGR
PROV
PROV
Annualised
PROV
2.3%
-13.2%
ABUS

Income Statement — Q2 FY2025 vs Q2 FY2026

Metric
ABUS
ABUS
PROV
PROV
Revenue
$10.7M
$9.8M
Net Profit
$2.5M
$1.4M
Gross Margin
Operating Margin
13.9%
20.8%
Net Margin
23.5%
14.6%
Revenue YoY
522.2%
2.5%
Net Profit YoY
112.7%
64.7%
EPS (diluted)
$0.01
$0.22

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABUS
ABUS
PROV
PROV
Q4 25
$9.8M
Q3 25
$9.7M
Q2 25
$10.7M
$9.8M
Q1 25
$10.1M
Q4 24
$9.6M
Q3 24
$9.5M
Q2 24
$9.9M
Q1 24
$9.4M
Net Profit
ABUS
ABUS
PROV
PROV
Q4 25
$1.4M
Q3 25
$1.7M
Q2 25
$2.5M
$1.6M
Q1 25
$1.9M
Q4 24
$872.0K
Q3 24
$1.9M
Q2 24
$2.0M
Q1 24
$1.5M
Operating Margin
ABUS
ABUS
PROV
PROV
Q4 25
20.8%
Q3 25
28.1%
Q2 25
13.9%
23.6%
Q1 25
26.2%
Q4 24
12.7%
Q3 24
28.3%
Q2 24
27.8%
Q1 24
22.5%
Net Margin
ABUS
ABUS
PROV
PROV
Q4 25
14.6%
Q3 25
17.3%
Q2 25
23.5%
16.7%
Q1 25
18.4%
Q4 24
9.1%
Q3 24
20.0%
Q2 24
19.7%
Q1 24
15.9%
EPS (diluted)
ABUS
ABUS
PROV
PROV
Q4 25
$0.22
Q3 25
$0.25
Q2 25
$0.01
$0.24
Q1 25
$0.28
Q4 24
$0.13
Q3 24
$0.28
Q2 24
$0.28
Q1 24
$0.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABUS
ABUS
PROV
PROV
Cash + ST InvestmentsLiquidity on hand
$37.4M
$54.4M
Total DebtLower is stronger
$0
Stockholders' EquityBook value
$83.0M
$127.5M
Total Assets
$103.3M
$1.2B
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABUS
ABUS
PROV
PROV
Q4 25
$54.4M
Q3 25
$49.4M
Q2 25
$37.4M
$53.1M
Q1 25
$50.9M
Q4 24
$45.5M
Q3 24
$48.2M
Q2 24
$51.4M
Q1 24
$51.7M
Total Debt
ABUS
ABUS
PROV
PROV
Q4 25
Q3 25
Q2 25
$0
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ABUS
ABUS
PROV
PROV
Q4 25
$127.5M
Q3 25
$128.4M
Q2 25
$83.0M
$128.5M
Q1 25
$128.9M
Q4 24
$128.6M
Q3 24
$129.6M
Q2 24
$129.9M
Q1 24
$129.5M
Total Assets
ABUS
ABUS
PROV
PROV
Q4 25
$1.2B
Q3 25
$1.2B
Q2 25
$103.3M
$1.2B
Q1 25
$1.3B
Q4 24
$1.3B
Q3 24
$1.3B
Q2 24
$1.3B
Q1 24
$1.3B
Debt / Equity
ABUS
ABUS
PROV
PROV
Q4 25
Q3 25
Q2 25
0.00×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABUS
ABUS
PROV
PROV
Operating Cash FlowLast quarter
$-15.7M
$1.2M
Free Cash FlowOCF − Capex
$1.0M
FCF MarginFCF / Revenue
10.5%
Capex IntensityCapex / Revenue
0.0%
1.9%
Cash ConversionOCF / Net Profit
-6.24×
0.85×
TTM Free Cash FlowTrailing 4 quarters
$14.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABUS
ABUS
PROV
PROV
Q4 25
$1.2M
Q3 25
$2.5M
Q2 25
$-15.7M
$8.7M
Q1 25
$3.3M
Q4 24
$324.0K
Q3 24
$2.6M
Q2 24
$5.7M
Q1 24
$3.0M
Free Cash Flow
ABUS
ABUS
PROV
PROV
Q4 25
$1.0M
Q3 25
$2.5M
Q2 25
$8.2M
Q1 25
$3.3M
Q4 24
$307.0K
Q3 24
$2.4M
Q2 24
$4.1M
Q1 24
$2.6M
FCF Margin
ABUS
ABUS
PROV
PROV
Q4 25
10.5%
Q3 25
25.2%
Q2 25
83.5%
Q1 25
32.5%
Q4 24
3.2%
Q3 24
25.1%
Q2 24
41.3%
Q1 24
27.5%
Capex Intensity
ABUS
ABUS
PROV
PROV
Q4 25
1.9%
Q3 25
0.5%
Q2 25
0.0%
5.4%
Q1 25
0.3%
Q4 24
0.2%
Q3 24
1.8%
Q2 24
16.0%
Q1 24
4.2%
Cash Conversion
ABUS
ABUS
PROV
PROV
Q4 25
0.85×
Q3 25
1.48×
Q2 25
-6.24×
5.34×
Q1 25
1.79×
Q4 24
0.37×
Q3 24
1.35×
Q2 24
2.91×
Q1 24
2.00×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons